VisiOn Restoration With FluidVisION Accommodating Intraocular Lens (AIOL)
Launched by POWERVISION · Apr 18, 2019
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
This study was originally designed as a single arm, unilateral study (one eye, one product only) to obtain an initial assessment of the safety and performance of an investigational IOL in subjects undergoing cataract extraction and IOL implantation. The study design was later modified to a contralateral study (both eyes, different product in each eye) to compare the safety and performance of the investigational IOL to a commercially available monofocal IOL.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Corrected distance visual acuity (CDVA) worse than 20/40, or presence of visually significant lens opacity;
- • Preoperative or predicted postoperative astigmatism of ≤ 1.0 diopter (D);
- • Calculated IOL power within range.
- Key Exclusion Criteria:
- • Current medication that may affect accommodation;
- • Systemic disease or concomitant medication that may increase operative risk or confound results;
- • Ocular conditions that may predispose the subject for future complications;
- • Monocular subjects or subjects with significant permanent visual function loss in fellow eye;
- • Previous intraocular or corneal surgery in either eye that may confound the results or increase the risk to the subject, including implantation of a multifocal IOL or other presbyopic corrective surgery in the fellow eye;
- • Grade 4 cataract of any type.
About Powervision
PowerVision is a pioneering clinical trial sponsor dedicated to advancing innovative medical technologies and therapies. With a focus on improving patient outcomes, PowerVision employs a rigorous scientific approach to research and development, ensuring the highest standards of safety and efficacy in its clinical trials. The organization collaborates with leading healthcare professionals and institutions to facilitate groundbreaking studies that drive the future of healthcare. Committed to transparency and ethical practices, PowerVision aims to deliver transformative solutions that enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials